Celyad announced the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise, effective January 4, 2016.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2795 EUR | +1.45% |
|
-0.18% | -28.33% |
04-04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.33% | 12.33M | |
+16.59% | 44.44B | |
+42.21% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.78% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Celyad Appoints Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise